1. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima^®) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts

   • Daniel L. Gustafson
   • Barbara Frederick
   • David Raben

   Original Article 29 March 2007 Pages: 179 - 188

   

2. Cell death in response to antimetabolites directed at thymidylate synthase

   • Karen W. Barbour
   • Franklin G. Berger

   Original Article 30 March 2007 Pages: 189 - 201

   

3. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro

   • Peter Andrews
   • Xu Zhao
   • Melissa Chang

   Original Article 20 April 2007 Pages: 203 - 214

   

4. Glutamine and alanyl-glutamine accelerate the recovery from 5-fluorouracil-induced experimental oral mucositis in hamster

   • R. F. C. Leitão
   • R. A. Ribeiro
   • G. A. C. Brito

   Original Article 11 April 2007 Pages: 215 - 222

   

5. Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis

   • Sandhya Kiran Apparaju
   • Gary A. Gudelsky
   • Pankaj B. Desai

   Original Article 19 April 2007 Pages: 223 - 229

   

6. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells

   • David H. Holman
   • Lorianne S. Turner
   • James S. Norris

   Original Article 12 April 2007 Pages: 231 - 242

   

7. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO

   • Jalid Sehouli
   • Dirk Stengel
   • on behalf of the Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO)

   Original Article 29 March 2007 Pages: 243 - 250

   

8. The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner

   • Hellinida Thomadaki
   • Andreas Scorilas
   • Maria Havredaki

   Original Article 09 May 2007 Pages: 251 - 265

   

9. Pharmacokinetics of the adrenocorticolytic compounds 3-methylsulphonyl-DDE and o,p′-DDD (mitotane) in Minipigs

   • Veronica Hermansson
   • Tatiana Cantillana
   • Ingvar Brandt

   Original Article 12 April 2007 Pages: 267 - 274

   

10. A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer

    • Takeshi Kato
    • Hideyuki Mishima
    • Morito Monden

    Original Article 11 April 2007 Pages: 275 - 281

    

11. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer

    • Bassel F. El-Rayes
    • Mark M. Zalupski
    • Philip A. Philip

    Original Article 12 April 2007 Pages: 283 - 289

    

12. Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system

    • Mark N. Kirstein
    • Richard C. Brundage
    • Douglas Yee

    Original Article 12 April 2007 Pages: 291 - 299

    

13. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy

    • Jong Gwang Kim
    • Baek-Yeol Ryoo
    • Yoon-Koo Kang

    Original Article 12 April 2007 Pages: 301 - 307

    

14. Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy

    • Hye Jin Choi
    • Byoung Chul Cho
    • Joo Hang Kim

    Original Article 19 June 2007 Pages: 309 - 313

    

15. A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer

    • Chong Kun Im
    • Hei-Cheul Jeung
    • Hyun Cheol Chung

    Original Article 02 June 2007 Pages: 315 - 321

    

16. Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2′deoxyribose (IPdR) × 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization

    • Timothy J. Kinsella
    • Michael T. Kinsella
    • Patricia J. Tosca

    Original Article 12 June 2007 Pages: 323 - 334

    

17. Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients

    • Takeharu Yamanaka
    • Shigemi Matsumoto
    • Masanori Fukushima

    Original Article 09 October 2007 Pages: 335 - 343

    

18. Reversible paclitaxel-induced vocal cord paralysis with later recall with vinorelbine

    • Brian S. Choi
    • H. Ian Robins

    Short Communication 20 March 2007 Pages: 345 - 346

19. Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda^®) monotherapy

    • Gregor Fürstenberger
    • Peter Schmid
    • Hans-Jörg Senn

    Short Communication 25 September 2007 Pages: 347 - 348